Taking its lead from the IOM report, the FDA is establishing an advisory committee on risk communications.
The committee will focus primarily on communications to the public, though it may also look at communication with physicians, said Crystal Rice of CDER media relations.
It will consist of patient and consumer representatives, as well as people with expertise in risk communication, social marketing, health literacy and the social sciences generally. The agency aims to empanel the committee quickly, said Rice, and while not permanent, it will probably be a long-term endeavor. “Given the continuing importance of effective communication about regulated products, our initial thoughts are that this committee will continue to be useful over time,” said Rice.
Other steps to improve drug safety announced by the agency include: a pilot program to assess the utility of postmarketing evaluation for routine new molecular entities; organizational and management changes to tighten communications between review and safety staff; more information sharing between FDA and the Veterans Health Administration; a CDER electronic safety tracking system; and an upgrade of the Adverse Events Reporting System database with new signal detection and tracking tools.
This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.